Zipcode Bio

Zipcode Bio is a U.S. biotechnology company focused on next-generation nucleic acid therapeutics. Co-founded by Dr. Jason Zhang and Dr. Drew Weissman—the 2023 Nobel Laureate in Physiology or Medicine for his pioneering work on mRNA vaccines—the company applies cutting-edge RNA expertise to address critical unmet medical needs. Zipcode Bio's proprietary SHARP™ (Single-component Homogeneous Amphiphilic Routed Particles) technology delivers nucleic acid therapeutics efficiently to the spleen and lungs. This platform offers advantages over traditional lipid nanoparticles (LNPs), including easier production, improved efficacy, and better safety. The company also uses advanced machine learning tools, with research published in Nature Machine Intelligence, to enhance therapeutic design. Zipcode Bio’s current pipeline includes mRNA vaccines and treatments for lung diseases. The company has built multiple high-quality collaborations with Universities and Industries to expand its portfolio. With a team dedicated to innovation and precision, Zipcode Bio is developing groundbreaking therapeutics to improve healthcare and shape the future of medicine.